Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1531 to 1540 of 2575 total matches.

Oxycodone OxyContin

   
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001  (Issue 1113)
to morphine has ranged from 0.7 to 1.5. Parenteral oxycodone is 10 to 12 times as potent as codeine. Oral ...
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Med Lett Drugs Ther. 2001 Sep 17;43(1113):80-1 |  Show IntroductionHide Introduction

Arrhythmias From Droperidol?

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002  (Issue 1132)
anesthesiologists consider droperidol in doses of 0.625-1.25 mg IV the drug of choice for patients at high risk ...
The FDA has added a "black box" warning about the risks of QT prolongation and the potentially fatal torsades de pointes (TdP) ventricular tachycardia to the labeling of droperidol (Inapsine - Akorn), an antiemetic used mostly in anesthesia. The Canadian Health Protection Branch has issued a similar warning. Some anesthesiologists have written to The Medical Letter to express their displeasure with these warnings.
Med Lett Drugs Ther. 2002 Jun 10;44(1132):53-4 |  Show IntroductionHide Introduction

Over-the-counter Omeprazole (Prilosec OTC)

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003  (Issue 1162)
). SOME OTC DRUGS FOR HEARTBURN Drug Dosage 1 Cost 2 H 2 -BLOCKERS Cimetidine − average generic ...
The FDA recently approved the proton pump inhibitor omeprazole magnesium (Prilosec OTC) for over-the-counter use for treatment of frequent heartburn. It will be marketed in late September or early October. Five proton pump inhibitors, including omeprazole, are available by prescription in the US (Medical Letter 2001; 43:36).
Med Lett Drugs Ther. 2003 Aug 4;45(1162):61-2 |  Show IntroductionHide Introduction

Parcopa: A Rapidly Dissolving Formulation of Carbidopa/Levodopa

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005  (Issue 1201)
- and controlled-release tablets. 1 THE NEW FORMULATION — The orally dissolving tablets can be taken ...
An orally dissolving, immediate-release tablet formulation of carbidopa/levodopa (Parcopa - Schwarz) that can be taken without water is now available for treatment of Parkinson's disease.
Med Lett Drugs Ther. 2005 Jan 31;47(1201):12 |  Show IntroductionHide Introduction

In Brief: Melamine

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
injury appeared to be the cause. 1 Melamine (C 3 H 6 N 6 ) is a heterocyclic compound, twothirds ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81 |  Show IntroductionHide Introduction

In Brief: Plan B for 17-Year Olds

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
to the emergency contraceptive Plan B 1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75 ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
Med Lett Drugs Ther. 2009 May 18;51(1312):40 |  Show IntroductionHide Introduction

Bupivacaine Liposome Injection (Exparel) for Postsurgical Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 2012  (Issue 1387)
, which cause fewer adverse effects.1,2 Local anesthetics such as bupivacaine are commonly administered ...
The FDA has approved a new formulation (Exparel – Pacira) of the local anesthetic bupivacaine (Marcaine, and others) for use in the management of postsurgical pain in adults.
Med Lett Drugs Ther. 2012 Apr 2;54(1387):26-7 |  Show IntroductionHide Introduction

Choice of Drug-Eluting Stents

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012  (Issue 1406)
stents (DESs) have largely replaced bare-metal stents (BMSs).1 BARE-METAL STENTS — Intracoronary stents ...
The use of intracoronary stents in angioplasty procedures has improved both short- and long-term success rates. In recent years, drug-eluting stents (DESs) have largely replaced bare-metal stents (BMSs).
Med Lett Drugs Ther. 2012 Dec 24;54(1406):102-3 |  Show IntroductionHide Introduction

Apremilast (Otezla) for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • May 26, 2014  (Issue 1443)
to 40% of patients with psoriasis develop psoriatic arthritis.1 Nonsteroidal anti-inflammatory drugs ...
Apremilast (Otezla – Celgene), an oral phosphodiesterase type-4 (PDE4) inhibitor, has been approved by the FDA for treatment of active psoriatic arthritis in adults. It is the fi rst PDE4 inhibitor to be approved for this indication.
Med Lett Drugs Ther. 2014 May 26;56(1443):41-2 |  Show IntroductionHide Introduction

Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 2016  (Issue 1507)
of the protein dystrophin in muscle cells. Dystrophin is essential for maintenance of myocyte integrity.1 About ...
Eteplirsen (Exondys 51 – Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation of the dystrophin gene that is amenable to exon 51 skipping. It is the first drug to be approved for treatment of DMD.
Med Lett Drugs Ther. 2016 Nov 7;58(1507):145-6 |  Show IntroductionHide Introduction